Guerbet S. A. (GBT) - Total Assets

Latest as of June 2025: €1.02 Billion EUR ≈ $1.19 Billion USD

Based on the latest financial reports, Guerbet S. A. (GBT) holds total assets worth €1.02 Billion EUR (≈ $1.19 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Guerbet S. A. for net asset value and shareholders' equity analysis.

Guerbet S. A. - Total Assets Trend (2004–2024)

This chart illustrates how Guerbet S. A.'s total assets have evolved over time, based on quarterly financial data.

Guerbet S. A. - Asset Composition Analysis

Current Asset Composition (December 2024)

Guerbet S. A.'s total assets of €1.02 Billion consist of 56.9% current assets and 43.1% non-current assets.

Asset Category Amount (EUR) % of Total Assets
Cash & Equivalents €0.00 4.8%
Accounts Receivable €209.07 Million 20.2%
Inventory €305.68 Million 29.5%
Property, Plant & Equipment €0.00 0.0%
Intangible Assets €77.91 Million 7.5%
Goodwill €28.77 Million 2.8%

Asset Composition Trend (2004–2024)

This chart illustrates how Guerbet S. A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Guerbet S. A. (GBT) total market value.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Guerbet S. A.'s current assets represent 56.9% of total assets in 2024, a decrease from 60.6% in 2004.
  • Cash Position: Cash and equivalents constituted 4.8% of total assets in 2024, up from 4.8% in 2004.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 10.0% in 2004.
  • Asset Diversification: The largest asset category is inventory at 29.5% of total assets.

Guerbet S. A. Competitors by Total Assets

Key competitors of Guerbet S. A. based on total assets are shown below.

Company Country Total Assets
Demant A/S
CO:DEMANT
Denmark Dkr39.07 Billion
Double Medical Technology Inc
SHE:002901
China CN¥4.55 Billion
Beijing Wandong Medical Technology Co Ltd
SHG:600055
China CN¥5.70 Billion
Sinocare Inc
SHE:300298
China CN¥6.25 Billion
MODULIGHT OY EO 1
F:78W
Germany €49.14 Million
Diagnostic Medical Systems SA
PA:ALDMS
France €57.17 Million
Theradiag SA
PA:ALTHE
France €11.55 Million
Nova EYE Medical Ltd
AU:EYE
Australia AU$23.67 Million

Guerbet S. A. - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.32 2.52 2.21
Quick Ratio 1.03 1.16 1.20
Cash Ratio 0.00 0.00 0.00
Working Capital €333.80 Million €364.31 Million €263.74 Million

Guerbet S. A. - Advanced Valuation Insights

This section examines the relationship between Guerbet S. A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.47
Latest Market Cap to Assets Ratio 0.16
Asset Growth Rate (YoY) 1.2%
Total Assets €1.04 Billion
Market Capitalization $171.08 Million USD

Valuation Analysis

Below Book Valuation: The market values Guerbet S. A.'s assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Guerbet S. A.'s assets grew by 1.2% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Guerbet S. A. (2004–2024)

The table below shows the annual total assets of Guerbet S. A. from 2004 to 2024.

Year Total Assets Change
2024-12-31 €1.04 Billion
≈ $1.21 Billion
+1.17%
2023-12-31 €1.03 Billion
≈ $1.20 Billion
+9.11%
2022-12-31 €939.64 Million
≈ $1.10 Billion
-6.11%
2021-12-31 €1.00 Billion
≈ $1.17 Billion
+5.83%
2020-12-31 €945.71 Million
≈ $1.11 Billion
-6.26%
2019-12-31 €1.01 Billion
≈ $1.18 Billion
-6.66%
2018-12-31 €1.08 Billion
≈ $1.26 Billion
+13.34%
2017-12-31 €953.59 Million
≈ $1.11 Billion
-7.25%
2016-12-31 €1.03 Billion
≈ $1.20 Billion
+13.92%
2015-12-31 €902.50 Million
≈ $1.06 Billion
+89.75%
2014-12-31 €475.63 Million
≈ $556.07 Million
+3.50%
2013-12-31 €459.55 Million
≈ $537.26 Million
-0.31%
2012-12-31 €460.97 Million
≈ $538.92 Million
+2.50%
2011-12-31 €449.72 Million
≈ $525.77 Million
+6.57%
2010-12-31 €422.01 Million
≈ $493.37 Million
+7.02%
2009-12-31 €394.32 Million
≈ $461.00 Million
+2.97%
2008-12-31 €382.96 Million
≈ $447.72 Million
+7.21%
2007-12-31 €357.21 Million
≈ $417.62 Million
+9.40%
2006-12-31 €326.51 Million
≈ $381.72 Million
+10.38%
2005-12-31 €295.81 Million
≈ $345.84 Million
+15.70%
2004-12-31 €255.67 Million
≈ $298.91 Million
--

About Guerbet S. A.

PA:GBT France Medical Devices
Market Cap
$171.08 Million
€146.34 Million EUR
Market Cap Rank
#17125 Global
#254 in France
Share Price
€11.60
Change (1 day)
+0.00%
52-Week Range
€8.20 - €23.55
All Time High
€76.51
About

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solut… Read more